Karma Biotechnologies: BREAKING CANCER’S IMMUNE DEFENSES
Karma Biotech is an oncology company targeting solid tumors, starting with colorectal cancer. Our technology aims to deliver cytokines and other biologicals, such as IL-15, specifically to tumor and metastatic sites, avoiding the dangers of systemic toxicity. This localized IL-15 will turn cold tumors hot, allowing the body to clear the cancer.
OUR TEAM
Karma is primed for success with a great mix of geeks and company builders
Andrew Gray, PhD
CO-FOUNDER & CEO
- PhD in Immune tolerance induced by cancer
- IndieBio alum
- Directs Karma’s synthetic bio strategy
Alan Johnson, MBA, BS
CO-FOUNDER & COO
- Synthetic chemist with 20+ years experience
- Iterates and validates Karma’s novel LNPs
Joe Turner
CFO & CBO
- Previously Managing Director at Blackstone/PJT
- MS Finance NYU
- Leads Karma’s finance and business strategy, including commercial partnerships
Xazmin Custer, PhD
MOLECULAR BIOLOGIST
- Metabolism & cell signaling expert
CONTACT US
Karma Biotechnologies
LOCATION
370 Amapola Avenue, Suite 101
Torrance, CA 90501
FOLLOW US ON SOCIAL MEDIA
LinkedIn
www.linkedin.com/company/karma-biotechnologies
Twitter
www.twitter.com/karmabiotech
Instagram
www.instagram.com/karmabiotech